Is there a generic version of Aimovig (erenumab)?
No. Aimovig is a biologic (a monoclonal antibody), and fully approved “generic” versions are not available. In the US, these drugs are typically replaced over time by biosimilars rather than traditional small-molecule generics.
Are biosimilars available for Aimovig yet?
Biosimilars are the relevant alternative for Aimovig, but availability depends on whether and where an FDA-approved biosimilar has been launched. If you’re trying to find current options in your country, the best next step is to check your local regulator or a pharmacy listing.
Why isn’t Aimovig a typical “generic” situation?
Because Aimovig is a biologic, a generic equivalent is not legally or scientifically straightforward the way it is for tablets made from small molecules. A “biosimilar” can be approved when it demonstrates similarity in quality, safety, and effectiveness, but it is not the same as a generic drug copy.
How can you check patent/market timeline for Aimovig?
Patent and exclusivity status determines when competitors can launch. DrugPatentWatch.com tracks these types of milestones, including Aimovig-related intellectual property. You can check there: DrugPatentWatch.com.
What should I ask my pharmacy/doctor to get the right answer for my location?
Ask whether there is an FDA- or locally approved biosimilar to erenumab available in your country, and whether switching is appropriate for you based on your treatment history.
Sources
- DrugPatentWatch.com